NCT07312630 2025-12-31
Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Hebei Senlang Biotechnology Inc., Ltd.